These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12785726)

  • 1. SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair.
    Zhong X; Li QQ; Reed E
    Cell Mol Life Sci; 2003 Apr; 60(4):794-802. PubMed ID: 12785726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells.
    Zhong X; Li X; Wang G; Zhu Y; Hu G; Zhao J; Neace C; Ding H; Reed E; Li QQ
    Int J Oncol; 2004 Aug; 25(2):445-51. PubMed ID: 15254743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
    Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
    Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
    Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.
    Li Q; Gardner K; Zhang L; Tsang B; Bostick-Bruton F; Reed E
    J Biol Chem; 1998 Sep; 273(36):23419-25. PubMed ID: 9722577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway.
    Zhong XS; Zheng JZ; Reed E; Jiang BH
    Biochem Biophys Res Commun; 2004 Nov; 324(2):471-80. PubMed ID: 15474452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells.
    Li QQ; Ding L; Reed E
    Res Commun Mol Pathol Pharmacol; 2000; 107(5-6):387-96. PubMed ID: 11589365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
    Li Q; Yu JJ; Mu C; Yunmbam MK; Slavsky D; Cross CL; Bostick-Bruton F; Reed E
    Anticancer Res; 2000; 20(2A):645-52. PubMed ID: 10810335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK.
    Li QQ; Lee RX; Liang H; Wang G; Li JM; Zhong Y; Reed E
    Int J Oncol; 2013 Sep; 43(3):721-8. PubMed ID: 23817665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line.
    Hayakawa J; Ohmichi M; Kurachi H; Ikegami H; Kimura A; Matsuoka T; Jikihara H; Mercola D; Murata Y
    J Biol Chem; 1999 Oct; 274(44):31648-54. PubMed ID: 10531373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors.
    Mimnaugh EG; Yunmbam MK; Li Q; Bonvini P; Hwang SG; Trepel J; Reed E; Neckers L
    Biochem Pharmacol; 2000 Nov; 60(9):1343-54. PubMed ID: 11008128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells.
    Li Q; Tsang B; Bostick-Bruton F; Reed E
    Biochem Pharmacol; 1999 Feb; 57(4):347-53. PubMed ID: 9933022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.
    Persons DL; Yazlovitskaya EM; Cui W; Pelling JC
    Clin Cancer Res; 1999 May; 5(5):1007-14. PubMed ID: 10353733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
    Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG
    Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line.
    Li Q; Bostick-Bruton F; Reed E
    Anticancer Res; 1998; 18(4A):2283-7. PubMed ID: 9703867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells.
    Li Q; Ding L; Yu JJ; Mu C; Tsang B; Bostick-Bruton F; Reed E
    Int J Oncol; 1998 Nov; 13(5):987-92. PubMed ID: 9772291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
    Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
    Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCAAT/Enhancer-binding protein-homologous protein sensitizes to SU5416 by modulating p21 and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Horm Metab Res; 2013 Jan; 45(1):9-14. PubMed ID: 22918703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
    Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.